Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis
Annals of Neurology · 2024-12 · 96 (6) · 1040-1057
DOI: 10.1002/ana.27054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 23.08.2024. Verfasst von Simon Witzel und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Ulm University, Ulm, Germany. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Biomarkers, Neurofilament Proteins. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Objective
Neurofilament light chains (NfL) and phosphorylated neurofilament heavy chains (pNfH), established as diagnostic and prognostic biomarkers in hospital‐based amyotrophic lateral sclerosis (ALS) cohorts, are now surrogate markers in clinical trials. This study extends their evaluation to a population level, with the aim of advancing their full establishment and assessing the transferability of biomarker findings from controlled cohorts to real‐world ALS populations.
Methods
We measured serum NfL and pNfH levels in all ALS patients (n = 790) and general population controls (n = 570) with available baseline samples participating in the epidemiological ALS Registry Swabia, providing platform‐specific (ELLA™) reference data and Z‐scores for controls, as well as reference data, disease‐specific Z‐scores and longitudinal data in ALS. We evaluated the diagnostic and prognostic utility of neurofilaments and quantified the impact of ALS‐related factors and non‐ALS confounders.
Results
Neurofilaments showed high diagnostic and prognostic utility at the population level, with NfL superior to pNfH. The novel concept of a population‐based ALS Z‐score significantly improved the prognostic utility compared to absolute raw values. Both biomarkers increased more strongly with age in controls than in ALS, and age adjustment improved diagnostic accuracy. Our data show that disease progression rates, ALS phenotype, body mass index (BMI), and renal function need to be considered when interpreting neurofilament levels; longitudinal neurofilament levels were generally stable in individual patients, especially when adjusted for age and baseline levels.
Interpretation
Population‐based assessment enhances the utility of particularly serum NfL as a diagnostic and prognostic biomarker in ALS and improves the translation of findings from controlled cohorts to real‐world populations. ANN NEUROL 2024;96:1040–1057
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Ulm University, Ulm, Germany.
- Institute for Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
- Department of Neurology, Klinikum Stuttgart, Katharinenhospital, Stuttgart, Germany.
- Department of Neurology, RKH Klinikum Ludwigsburg, Ludwigsburg, Germany.
- Department of Neurology, Klinikum Kaufbeuren, Kliniken Ostallgaeu-Kaufbeuren, Kaufbeuren, Germany.
- Department of Neurology, Klinikum am Gesundbrunnen Heilbronn, Heilbronn, Germany.
ORCID-Profile: Simon Witzel, Angela Rosenbohm, David Brenner, Johannes Dorst
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Witzel, S., Huss, A., Nagel, G., Rosenbohm, A., Rothenbacher, D., Peter, R. S., Bäzner, H., Börtlein, A., Dempewolf, S., Schabet, M., Hecht, M., Kohler, A., Opherk, C., Naegele, A., Sommer, N., Lindner, A., Alexudis, C., Bachhuber, F., Halbgebauer, S., …, & the ALS Registry Swabia Study Group (2024). Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis. Annals of Neurology, 96(6), 1040-1057. https://doi.org/10.1002/ana.27054
Vancouver
Witzel S, Huss A, Nagel G, Rosenbohm A, Rothenbacher D, Peter RS, et al. Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis. Annals of Neurology. 2024;96(6):1040-1057. doi:10.1002/ana.27054
BibTeX
@article{Witzel2024,
author = {Witzel, Simon and Huss, André and Nagel, Gabriele and Rosenbohm, Angela and Rothenbacher, Dietrich and Peter, Raphael S and Bäzner, Hansjörg and Börtlein, Axel and Dempewolf, Silke and Schabet, Martin and Hecht, Martin and Kohler, Andreas and Opherk, Christian and Naegele, Andrea and Sommer, Norbert and Lindner, Alfred and Alexudis, Christoforos and Bachhuber, Franziska and Halbgebauer, Steffen and Brenner, David and Ruf, Wolfgang and Weiland, Ulrike and Mayer, Benjamin and Schuster, Joachim and Dorst, Johannes and Tumani, Hayrettin and Ludolph, Albert C and the ALS Registry Swabia Study Group, the ALS Registry Swabia Study Group},
title = {Population‐Based Evidence for the Use of Serum Neurofilaments as Individual Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis},
journal = {Annals of Neurology},
year = {2024},
volume = {96},
number = {6},
pages = {1040--1057},
doi = {10.1002/ana.27054}
}
EUVIMED